microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome

BACKGROUND: Gastrointestinal stromal tumour (GIST) is mainly initialised by receptor tyrosine kinase gene mutations. Although the tyrosine kinase inhibitor imatinib mesylate considerably improved the outcome of patients, imatinib resistance still remains a major therapeutic challenge in GIST therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Akçakaya, P, Caramuta, S, Åhlen, J, Ghaderi, M, Berglund, E, Östman, A, Bränström, R, Larsson, C, Lui, W-O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260040/
https://www.ncbi.nlm.nih.gov/pubmed/25349971
http://dx.doi.org/10.1038/bjc.2014.548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260040/
https://www.ncbi.nlm.nih.gov/pubmed/25349971
http://dx.doi.org/10.1038/bjc.2014.548

Ejemplares similares